Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1998, for Bioanalytical Systems, Inc. (Note: The input metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.). The Company manufactures scientific instruments for trace organic compound determination and provides laboratory services, consulting, and research. The fiscal year ends September 30.
Key Financial Metrics
| Metric | Three Months Ended June 30, 1998 | Nine Months Ended June 30, 1998 |
|---|---|---|
| Total Revenue | $4.52 million | $13.30 million |
| Gross Profit | $2.51 million | $7.55 million |
| Operating Income | $0.25 million | $0.90 million |
| Net Income | $0.13 million | $0.56 million |
| Diluted EPS | $0.03 | $0.13 |
| Cash and Equivalents (End of Period) | $2.66 million | |
| Long-Term Debt (End of Period) | $0.04 million | |
| Lines of Credit (End of Period) | $0.00 million |
Liquidity: The Company holds $2.66 million in cash and cash equivalents, a significant increase from $161,000 at the prior fiscal year-end, driven by an Initial Public Offering (IPO) in November 1997. A $7.5 million bank line of credit is available but currently unutilized.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 17.7% for the quarter and 20.9% for the nine-month period compared to the prior year. This was driven by a 45.3% increase in services revenue (quarterly) and a 9.2% increase in product revenue.
- Profitability Decline: Despite revenue growth, Net Income decreased 40.4% for the quarter ($0.22M to $0.13M) and 17.0% for the nine-month period ($0.67M to $0.56M). Operating income dropped 31.6% for the quarter.
- Expense Increases: Research and Development (R&D) expenses surged 58.2% (quarterly) due to accelerated product development and grant projects. General and Administrative (G&A) expenses rose 13.6% (quarterly) due to patent litigation defense and facility expansion costs.
- Debt Reduction: Long-term debt was reduced from $5.33 million (Sep 1997) to $0.13 million (Jun 1998) using IPO proceeds.
Outlook, Risks, and Unusual Items
- Acquisitions: The Company acquired Vetronics, Inc. (Oct 1997) and Clinical Innovations Ltd. (Jul 1998, subsequent event) to expand physiology monitoring and pharmaceutical service capabilities.
- Capital Expenditures: The Company anticipates increased capital expenditures for the remainder of fiscal 1998 and 1999 for facility construction and equipment purchases.
- Legal Proceedings: The Company is defending a patent infringement suit filed by CMA Microdialysis Holding A.B. regarding microdialysis probes. While management believes the outcome will not be materially adverse, legal expenses are impacting earnings.
- Geographic Risks: Reduced sales in Asia due to currency fluctuations were offset by improvements in North and South America.
- Forward-Looking Statements: Management cautions that future profitability and strategic plans are subject to risks and uncertainties, including industry trends and capital requirements.
Investor Verification Checklist
- Verify the sustainability of the 45% growth in services revenue versus the 9% growth in product revenue.
- Monitor the impact of the CMA Microdialysis patent litigation on future G&A expenses and potential liability.
- Assess the return on investment for the significant increase in R&D spending (up 58% YoY).
- Confirm the integration progress and revenue contribution of the Vetronics and Clinical Innovations acquisitions.
- Review the utilization of the $7.5 million credit line and the timeline for planned facility construction expenditures.